佳罗华维持期间要是感染新冠会发生什么，好担心啊！

马西西 · 发表于 2022-12-2 22:35:27

维持期间B细胞为零，好像B细胞就是负责抗病毒的，要是B细胞缺失的话，感染新冠会不会特别严重，现在感到有点恐慌，有研究过或有听说过这方面信息的吗？

来自苹果APP客户端

新鲜空气 · 发表于 2022-12-2 23:25:47

没办法，只能看天意，看身体状况。我也才打了，无奈叹息

来自安卓APP客户端

平凡一生 · 发表于 2022-12-2 23:27:00

加油！

来自安卓APP客户端

老爸再陪我30年 · 发表于 2022-12-3 06:11:59

抵抗力太弱，只能好好防护，其他的没办法

来自苹果APP客户端

.T淋巴母淋巴瘤 · 发表于 2022-12-3 08:31:02

尽量做好防护，买个测心率，血氧的智能手环或者手表，发现不对赶紧去医院

来自安卓APP客户端

小猪泡泡 · 发表于 2022-12-3 10:08:16

b细胞打没了，免疫力低下。还是得注意防护

来自安卓APP客户端

橙色雨丝 · 发表于 2022-12-3 10:16:02

Impact of rituximab on COVID-19 outcomes

DOI: 10.1007/s00277-021-04662-1

Abstract

Rituximab is associated with prolonged B-cell depletion and secondary hypogammaglobulinemia and is associated with a dampened humoral response and increased infectious complications. To describe the potential impact of prior rituximab therapy on clinical outcomes from SARS-CoV-2 infection and development of COVID-19 antibodies, we conducted a retrospective study of adults across the Mount Sinai Health System diagnosed with COVID-19 who received rituximab for any indication from February 2019 to October 2020. Patients' baseline characteristics, markers of disease severity, clinical outcomes, and antibody development were examined. Of the 49 patients included in the analysis, 63.2% required hospitalization for COVID-19, 24.5% required an ICU admission, and 32.7% died. Proximity of last rituximab infusion and COVID-19 diagnosis did not affect rates of hospitalization, admission to intensive care units or death. Over half (51.7%) of those whose antibodies were checked developed neutralizing anti-spike protein antibodies. The median time between rituximab administration and COVID-19 diagnosis was not significantly different between those who developed antibodies and those who did not (p = .323). Of the 14 patients with documented negative COVID-19 antibody titers, 11 of them survived SARS-CoV-2 infection, indicating that development of neutralizing antibodies may not be necessary for recovery from COVID-19.

利妥昔单抗与B细胞耗竭延长和继发性低丙种球蛋白血症相关，并与体液反应减弱和感染并发症增加相关。为了描述先前利妥昔单抗治疗对SARS-CoV-2感染临床结果和新冠肺炎抗体发展的潜在影响，我们对2019年2月至2020年10月期间西奈山卫生系统确诊为新冠肺炎的成年人进行了一项回顾性研究，这些成年人接受利妥昔单抗治疗，以确定其适应症，检查临床结果和抗体开发。在纳入分析的49名患者中，63.2%的患者因新冠肺炎需要住院治疗，24.5%的患者需要ICU入院治疗，32.7%的患者死亡。最后一次输注利妥昔单抗和新冠肺炎诊断的接近程度并不影响住院率、重症监护室入院率或死亡率。超过一半（51.7%）的抗体被检测出中和性抗刺突蛋白抗体。在出现抗体的患者和没有出现抗体的人群中，利妥昔单抗给药与新冠肺炎诊断之间的中位数时间没有显著差异（p=0.323）。在14名新冠肺炎抗体滴度呈阴性的患者中，11名患者存活下来，这表明中和抗体的产生可能不是新冠肺炎痊愈的必要条件。